Powered by

Galectin Therapeutics Announces Achievement of Key Milestones Related to NASH-CX Clinical Trial

Feb 01, 2017 - GlobeNewswire

NORCROSS, Ga., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced it has generated sufficient financing to cover currently planned expenditures through 2017 and it remains on track to present top line data from its NASH-CX Phase 2 clinical trial by early December 2017. 

Through the sale of common stock via the Company's At-The Market sales agreement, and previously announced pri...